SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending following a trading halt prompted by the news that its drug tovecimig did not meet the overall survival secondary endpoint in a Phase 2/3 study. The community is actively debating the implications for the company's regulatory path and future BLA filing, with significant skepticism regarding the trial design and statistical outcomes.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is trending following positive interim Phase 2a results for ORKA-001 in psoriasis, which hit its primary endpoint and showed potential for annual dosing. The community is actively debating the company's long-term valuation compared to sector peers and monitoring potential dilution as the firm moves toward larger late-stage trials.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to a significant revenue outlook miss for the upcoming quarter and broader memory supply constraints that are pressuring smartphone handset sales. Community sentiment is deeply divided, with many debating the impact of these headwinds versus the potential for long-term growth through AI-powered smartphone chips, upcoming automotive design wins, and aggressive stock buyback programs.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is facing intense volatility following a mixed earnings report and the filing of a $500 million shelf registration, which has triggered community debate regarding potential future dilution. While some investors remain optimistic about the company's long-term integration into the aerospace and defense supply chains, others are closely watching the balance sheet and the transition to new financial leadership.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is drawing significant investor focus as the stock navigates a challenging consumer environment, with community discourse centered on whether its recent earnings and profitability metrics signal a buying opportunity or further volatility. While some investors remain bullish on the company's long-term franchise stability and dividend growth, many are actively debating the impact of inflationary pressures and evolving delivery competition on its competitive moat.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton Interactive is drawing significant community attention as investors debate its potential for a turnaround and a possible short squeeze, fueled by analyst commentary on its free cash flow and recent cost-cutting measures. Discussions center on whether the company's hardware pivots and subscription stabilization will spark a rebound or if ongoing subscriber churn and macroeconomic headwinds will keep the stock under pressure.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors rotate into defensive, high-yield dividend stocks amid broader market volatility, further fueled by operational momentum from the company's recent earnings beat and aggressive share buyback program. The community is actively discussing its potential for sustained growth as it captures market share through competitive pricing, with many monitoring the $50 resistance level as a key psychological milestone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FTC announced that StubHub has agreed to refund $10 million in fees to affected consumers.</li><li>The agency added that StubHub’s pricing displays on its website did not include all the mandatory fees.</li><li>The FTC has directed StubHub to process refunds within 90 days of the order date for consumers who bought tickets for live events on the platform between May 12, 2025, and May 14, 2025.</li></ul>Shares of StubHub Holdings Inc. (STUB) hit a new all-time low on Thursday after the U.S. Federal Trade Commission (FTC) reportedly sued the company, alleging deceptive ticket pricing policies.The FTC alleged that StubHub failed to display&nbsp;the full ticket prices to buyers.<a href="https://stocktwits.com/symbol/STUB">StubHub shares</a> were down nearly 8% in Thursday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">StubHub To Refund $10M In Fees To Consumers</h2>The FTC announced that StubHub has agreed to refund $10 million in fees to affected consumers, making them whole.“The Commission’s Fees Rule makes it very clear that the total price of live-event tickets must be disclosed up-front to enable consumers to make fully informed purchasing decisions,” said Christopher Mufarrige, Director of the FTC’s Bureau of Consumer Protection.The FTC said StubHub did not clearly display the full ticket price, including for National Football League events, when the schedule was released on May 14, 2025. The agency added that StubHub’s pricing displays on its website did not include all the mandatory fees.Eligible buyers will receive monetary relief from StubHub through a settlement and consumer redress distribution program, the FTC stated.The agency has directed StubHub to process refunds within 90 days of the order date for consumers who bought tickets for live events on the platform between May 12, 2025, and May 14, 2025.<h2 class="st-heading-2">What Is The FTC Rule About?</h2>Under the FTC’s rule on Unfair and Deceptive Fees, it is considered an unfair and deceptive practice for any business to offer, display, or advertise the price of a live-event ticket without clearly and prominently disclosing the total cost.The FTC defines this total as the maximum amount a consumer must pay, including all mandatory fees and charges for the ticket and any required ancillary goods or services, excluding only taxes, shipping, and optional add-ons selected by the consumer.The rule was announced in December 2024 and came into effect on May 12, 2025.<a href="https://stocktwits.com/symbol/STUB">STUB stock</a> is down 57% year-to-date. The Global X Guru Index ETF (GURU) is up 33% over the past 12 months, while the Vanguard Small-Cap Value Index Fund ETF (VBR) is up 28%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apld-stock-tumbles-despite-q3-beat-analyst-says-buy-on-weakness/cZJWOcsRIse">APLD Stock Tumbles Despite Q3 Beat — Analyst Says Applied Digital Remains A 'Top Pick', Recommends Buying On Weakness</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The StubHub logo and webpage are displayed on a cell phone and computer monitor. (Photo Illustration by Mario Tama/Getty Images)

STUB Stock Sinks To All-Time Low After FTC Sues StubHub Over Alleged Deceptive Ticket Pricing Practices

The FTC alleged that StubHub failed to display the full pricing of tickets to buyers.

Equity

<ul class="summary-bullets"><li>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12.</li><li>The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.</li><li>Wedbush stated that it has “limited conviction and visibility” regarding StubHub’s direct issuance business.</li></ul>StubHub Holdings Inc.’s (STUB) lackluster fourth-quarter (Q4) results drew a spate of downgrades from Wall Street, with analysts pointing to a series of concerns about the company’s future outlook and the regulatory environment.<a href="https://stocktwits.com/symbol/STUB">StubHub shares</a> tumbled more than 14% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Worried?</h2>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12. The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.JPMorgan stated that StubHub’s 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance is now 60% lower than what the company projected in October 2025. The firm said that while the new outlook “may finally be achievable,” it will have to work through the lock-up expiration beginning March 9, 2026, and also overcome ongoing regulatory concerns around the company.Analysts at Wedbush also downgraded StubHub to ‘neutral’ from ‘outperform’ and lowered the price target by 80% to $10 from $18. The firm stated that it has “limited conviction and visibility” in StubHub’s direct issuance business, noting that the ticket resale broker’s management’s “lofty” expectations are not materializing.Wedbush also stated that regulatory risks will remain an overhang on the stock, while adding that the company is vulnerable to AI-enabled disintermediation in the coming years, given that companies operating in the space face the risk from commoditization.<h2 class="st-heading-2">StubHub’s Q4 At A Glance</h2>StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share (EPS) of $0.13 during the same quarter a year ago. Wall Street expected the company to report a loss of $0.02 per share during the quarter, according to Fiscal.ai data.The company’s revenue in Q4 was $449 million, down from $533 million in the year-ago period. Wall Street consensus projected StubHub to report revenue of $485 million during the period.StubHub’s founder and CEO, Eric Baker, remained optimistic about the company’s prospects, stating that 2025 reinforced that the ticket resale broker’s mission is as relevant as ever. “Our full-year performance validates our long-term strategy and the substantial value we're creating for fans, partners, and shareholders alike,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React To STUB?</h2>One user on Stocktwits pointed to macroeconomic challenges in the U.S., adding that the amount of money people have to spend on “luxuries” is declining.<stembedurl>https://stocktwits.com/insanitywolftrading/message/646656600</stembedurl>However, a bullish user said that StubHub is a “solid company with actually great earnings.”<stembedurl>https://stocktwits.com/llevi/message/646632021</stembedurl><a href="https://stocktwits.com/symbol/STUB">STUB stock</a> is down 25% year-to-date and 64% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-stock-soars-q4-beat-palladyne-ai-ceo-touts-deeper-defense-engagement/cZdQqg1RI3P">Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

StubHub's Q4 Miss Draws Multiple Downgrades From Wall Street – Analysts Warn Of ‘Credibility’ Gap

StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share of $0.13 during the same quarter a year ago, while Wall Street expected a loss of $0.02 per share.

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

GURU
Global X Funds - Global X Guru Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GURU News

GURUGlobal X Funds - Global X Guru Index ETF